ImmunoGen (IMGN) : 2 brokerage houses believe that ImmunoGen (IMGN) is a Strong Buy at current levels. 5 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on ImmunoGen (IMGN). Zacks Investment Research suggests a Hold with a rank of 3. 1 others believe that the stock has run up ahead of its fundamentals and advise a Strong Sell on the stock.The median of all the 8 Wall Street Analysts endorse the stock as a Hold with a rating of 2.66.
ImmunoGen (IMGN) : Currently there are 7 street experts covering ImmunoGen (IMGN) stock. The most bullish and bearish price target for the stock is $9 and $3 respectively for the short term. The average price target of all the analysts comes to $6.14. The estimated standard deviation from the target is $2.25.
For the current week, the company shares have a recommendation consensus of Buy. ImmunoGen (NASDAQ:IMGN): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $2.96 and $2.89 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $3.02. The buying momentum continued till the end and the stock did not give up its gains. It closed at $2.99, notching a gain of 2.05% for the day. The total traded volume was 1,335,276 . The stock had closed at $2.93 on the previous day.
In a related news,The officer (Executive Vice President) of Immunogen Inc, Lambert John sold 3,889 shares at $8.22 on February 1, 2016. The Insider selling transaction had a total value worth of $31,968. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
ImmunoGen, Inc. (ImmunoGen) is a clinical-stage biotechnology company focused on the development of targeted anticancer therapeutics. The Companys clinical and preclinical product candidates are antibody-drug conjugates (ADCs), which is a type of medicine that uses a monoclonal antibody to deliver a therapeutic agent to targeted cells. The Company has three clinical-stage anticancer compounds: mirvetuximab soravtansine (IMGN853), coltuximab ravtansine, IMGN529, and IMGN779. The Companys partners are Amgen Inc., Bayer HealthCare (a subgroup of Bayer AG), Biotest AG, Eli Lilly and Company (Lilly), Novartis Institutes for BioMedical Research, Inc. (Novartis), the Roche Group, Sanofi and Takeda. The Companys collaborative partner compounds include Kadcyla, Indatuximab ravtansine, Isatuximab, Anetumumab ravtansine, AMG 595, AMG 172, SAR566658, SAR408701, LOP628 and PCA062. All of the Companys compounds are ADCs with the exception of isatuximab, which is a therapeutic antibody.